Toxin and Immunotoxin Based Therapeutic Approaches

In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied anti...

Full description

Saved in:
Bibliographic Details
Other Authors: Bortolotti, Massimo (Editor), Polito, Letizia (Editor), Bolognesi, Andrea (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_78835
005 20220224
003 oapen
006 m o d
007 cr|mn|---annan
008 20220224s2022 xx |||||o ||| 0|eng d
020 |a books978-3-0365-3065-9 
020 |a 9783036530659 
020 |a 9783036530642 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-3065-9  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a H  |2 bicssc 
072 7 |a JFFP  |2 bicssc 
100 1 |a Bortolotti, Massimo  |4 edt 
700 1 |a Polito, Letizia  |4 edt 
700 1 |a Bolognesi, Andrea  |4 edt 
700 1 |a Bortolotti, Massimo  |4 oth 
700 1 |a Polito, Letizia  |4 oth 
700 1 |a Bolognesi, Andrea  |4 oth 
245 1 0 |a Toxin and Immunotoxin Based Therapeutic Approaches 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (122 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-based targeting strategies is the carrying of powerful toxins. The generated molecules are immunotoxins, i.e., chimeric proteins obtained by coupling bacterial or plant toxins and antibodies through chemical linking or genetic engineering. Immunotoxins are functionally designed to eliminate the cells responsible for pathological conditions, and they find applications in several fields, ranging from cancer to immunological diseases or pain control. Despite the lack of specificity, even native toxins find clinical application, but the use of unconjugated toxins is limited to loco-regional treatments. A fundamental requirement for the medical application of toxins and their immunoconjugates is in-depth knowledge of their interaction with target cells in terms of binding, uptake, intracellular routing, and substrate specificity. This Special Issue focuses on toxins and immunotoxins that have clinical potential. We hope to give the reader a comprehensive overview of new toxin delivery strategies and toxin-based experimental disease models, both in vitro and in vivo. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Humanities  |2 bicssc 
650 7 |a Social interaction  |2 bicssc 
653 |a 3D structure 
653 |a plant toxin 
653 |a primary sequence 
653 |a ribosome-inactivating protein 
653 |a stenodactylin 
653 |a toxic lectin 
653 |a fusion proteins 
653 |a ricin 
653 |a pokeweed antiviral protein 
653 |a COVID-19 
653 |a SARS-CoV-2 
653 |a antiviral agent 
653 |a ribosome-inactivating proteins 
653 |a monoclonal antibody 
653 |a immunotoxin 
653 |a antibody drug conjugate 
653 |a immunoliposome 
653 |a drug delivery 
653 |a diphtheria toxin 
653 |a DT3C 
653 |a prostate cancer 
653 |a targeted toxins 
653 |a epidermal growth factor 
653 |a epidermal growth factor receptor 
653 |a Pseudomonas Exotoxin A 
653 |a patient-derived glioblastoma cell lines 
653 |a Chenopodium quinoa wild 
653 |a quinoin 
653 |a temozolomide 
653 |a Glypican-3 
653 |a hepatocellular carcinoma 
653 |a humanized YP7 
653 |a new recombinant immunotoxin 
653 |a kirkiin 
653 |a sugar specificity 
653 |a cancer therapy 
653 |a n/a 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/4929  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/78835  |7 0  |z DOAB: description of the publication